Skip to content

A prospective, noninferiority trial exploring the necessity of postoperative radiotherapy for patients with pN1 stage head and neck cancer

A prospective, noninferiority trial exploring the necessity of postoperative radiotherapy for patients with pN1 stage head and neck cancer

Status
Recruiting
Phases
Phase 3
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2100042541
Enrollment
Unknown
Registered
2021-01-23
Start date
2022-09-01
Completion date
Unknown
Last updated
2024-08-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Head and neck squamous cell carcinoma

Interventions

Cervical radiation group:Patients in this group will receive adjuvant cervical radiation after neck dissection. The radiation mode is IMRT and the overall radiation dose should be 44-50Gy (2.0Gy/f) to
Cervical observation group:Patients in this group will not receive cervical radiation after neck dissection.

Sponsors

Sun Yat-Sen University Cancer Center
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1.Patients with head and neck squamous cell carcinoma who have received radical resection of primary lesions and neck dissection. The pathological stage of these patients should be pT1-3N1M0 (AJCC TNM staging system, eighth edition). The anatomic sites of primary lesions include oral cavity, oropharynx (HPV negative), larynx, and laryngopharynx. 2.Not receiving any other anti-tumor treatment except for the radical surgery. 3.No history of other malignancies. 4.Male or female, aged 18 to 75 years. 5.Adequate liver function: TBIL = 3.5 X 10^9/L; PLT >= 100 x 10^9/L; HGB >= 90g/L. 8. No severe dysfunction of major organs including heart and lung. 9. Performance status (PS) score <= 2. 10. Written informed consent.

Exclusion criteria

Exclusion criteria: 1. Women in pregnancy or lactation. 2. Patients who could not cooperate with regular follow-up due to any reasons. 3. Simultaneously receiving any experimental treatment of other clinical trials (in the treatment period of the clinical trial). 4. With severe and uncontrollable infectious or systematic diseases. 5. Long-term use of immunosuppressive agents after organ transplantation.

Design outcomes

Primary

MeasureTime frame
2-year regional recurrence-free survival (RRFS);

Secondary

MeasureTime frame
5-year overall survival (OS);5-year distant metastasis-free survival (DMFS);5-year progression-free survival (PFS);Safety;

Countries

China

Contacts

Public ContactMing Song

Sun Yat-Sen University Cancer Center

songming@sysucc.org.cn+86 13809771505

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026